Biogen
NEWS
The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.
It was a busy week for clinical trial announcements. Here’s a look.
The U.S. Court of Appeals for the Federal Circuit denied Biogen a second look into the patent dispute filed against Mylan for Biogen’s Multiple Sclerosis (MS) drug, Tecfidera.
Genentech shared new data from its SUNFISH study evaluating the use of Evrysdi for SMA people ages 2 to 25 years diagnosed with Type 2 or Type 3 spinal muscular atrophy.
Biogen returned the rights to a dry age-related macular degeneration (dAMD) drug to Catalyst Biosciences. Biogen also ended the partnership regarding other dry AMD.
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
In the latest results shared by the company, treatment with nusinersen for a median of 4.9 years helped participants maintain and make progressive gains in motor function.
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
JOBS
IN THE PRESS